ストックスクリーナーアプリを入手
2.21
2.64%
-0.06
前日終値:
$2.27
開ける：
$2.3
24時間の取引高:
1.71M
Relative Volume:
0.73
時価総額：
$743.81M
収益：
-
当期純損益:
$-75.80M
株価収益率:
-6.3143
EPS:
-0.35
ネットキャッシュフロー:
$-68.07M
1週間 パフォーマンス:
-2.64%
1か月 パフォーマンス:
-14.34%
6か月 パフォーマンス:
-21.07%
1年 パフォーマンス:
+24.16%
1日の値動き範囲:
$2.20
$2.33
1週間の範囲:
$2.20
$2.375
52週間の値動き範囲:
$1.67
$4.1598
Nuvation Bio Inc Stock (NUVB) Company Profile
名前
Nuvation Bio Inc
セクター
電話
(415) 754-3517
住所
357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO
NUVB を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NUVB
Nuvation Bio Inc
|
2.21 | 743.81M | 0 | -75.80M | -68.07M | -0.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Nuvation Bio Inc Stock (NUVB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-03-27 | アップグレード | Jefferies | Hold → Buy |
| 2024-03-26 | アップグレード | BTIG Research | Neutral → Buy |
| 2023-01-06 | ダウングレード | Jefferies | Buy → Hold |
| 2022-08-02 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2022-08-02 | ダウングレード | BTIG Research | Buy → Neutral |
| 2022-05-04 | 開始されました | H.C. Wainwright | Buy |
| 2021-10-15 | 再開されました | BTIG Research | Buy |
| 2021-04-06 | 開始されました | RBC Capital Mkts | Outperform |
| 2021-03-08 | 開始されました | BMO Capital Markets | Outperform |
| 2021-03-08 | 開始されました | BTIG Research | Buy |
| 2021-03-08 | 開始されました | Cowen | Outperform |
| 2021-03-08 | 開始されました | Jefferies | Buy |
| 2021-03-08 | 開始されました | Wedbush | Outperform |
すべてを表示
Nuvation Bio Inc (NUVB) 最新ニュース
Nuvation Bio Inc. (NYSE:NUVB) Short Interest Up 14.3% in January - MarketBeat
Kuehn Law Encourages Investors of Nuvation Bio Inc. to Contact Law Firm - Eastern Progress
What Do Wall Street Analysts Think About Nuvation Bio Inc (NYSE: NUVB) Stock? - Stocks Register
Peapod Lane Capital LLC Makes New $1.04 Million Investment in Nuvation Bio Inc. (NYSE:NUVB) - MarketBeat
Nuvation Bio executive departs after key milestones By Investing.com - Investing.com Nigeria
Nuvation Bio executive departs after key milestones - MSN
Nuvation BioPending Approval Shot In ROSL+ NSCLS Looks A Major Upside Catalyst (NUVB) - Seeking Alpha
Nuvation Bio CEO Departs After Achieving Key Goals - TipRanks
Bullish Nuvation Bio Insiders Loaded Up On US$720.1k Of Stock - Simply Wall St
Nuvation Bio Inc (NUVB)’s results reveal risk - US Post News
Nuvation Bio : Corporate Presentation (February 2025) - Marketscreener.com
The Significance of Moving Averages in Nuvation Bio Inc Inc. (NUVB) Price Performance - The InvestChronicle
Nuvation Bio Inc [NUVB] stock for 162,883 USD was sold by Wang Junyuan Jerry - Knox Daily
Understanding the Risks of Investing in Nuvation Bio Inc (NUVB) - Knox Daily
Nuvation Bio Inc (NUVB) requires closer examination - US Post News
Nuvation Bio Inc (NYSE: NUVB) Could Pass $7 In One Year Stock Forecast - Stocks Register
Nuvation Bio launches EAP for lung cancer drug taletrectinib - MSN
Nuvation Bio Starts Expanded Access Program for Lung Cancer Drug -February 03, 2025 at 10:41 am EST - Marketscreener.com
Nuvation Bio Announces Expanded Access Program in the U.S. for Taletrectinib in Advanced ROS1-positive Non-Small Cell Lung Cancer - Marketscreener.com
With 46% stake, Nuvation Bio Inc. (NYSE:NUVB) seems to have captured institutional investors' interest - Yahoo Finance
HC Wainwright Cuts Earnings Estimates for Nuvation Bio - Defense World
HC Wainwright Decreases Earnings Estimates for Nuvation Bio - MarketBeat
Assenagon Asset Management S.A. Sells 309,176 Shares of Nuvation Bio Inc. (NYSE:NUVB) - Defense World
JPMorgan Chase & Co. Increases Position in Nuvation Bio Inc. (NYSE:NUVB) - Defense World
JPMorgan Chase & Co. Grows Stock Holdings in Nuvation Bio Inc. (NYSE:NUVB) - MarketBeat
Assenagon Asset Management S.A. Reduces Stock Holdings in Nuvation Bio Inc. (NYSE:NUVB) - MarketBeat
Nuvation Bio (NYSE:NUVB) Price Target Raised to $11.00 - Defense World
Nuvation Bio (NYSE:NUVB) Shares Down 3.8%Here's What Happened - MarketBeat
HC Wainwright Forecasts Strong Price Appreciation for Nuvation Bio (NYSE:NUVB) Stock - MarketBeat
Nuvation Bio Inc. (NYSE:NUVB) Short Interest Update - MarketBeat
Nuvation Bio (NYSE:NUVB) Trading Down 5.6%Should You Sell? - MarketBeat
Jane Street Group LLC Decreases Stake in Nuvation Bio Inc. (NYSE:NUVB) - Defense World
Nuvation Bio Inc. (NYSE:NUVB) Holdings Decreased by Jane Street Group LLC - MarketBeat
HC Wainwright Predicts Stronger Earnings for Nuvation Bio - Defense World
FY2024 EPS Estimate for Nuvation Bio Increased by Analyst - MarketBeat
Nuvation Bio (NYSE:NUVB) Stock Price Down 8.3%Here's Why - MarketBeat
Nuvation Bio's SWOT analysis: oncology firm's stock faces pivotal year By Investing.com - Investing.com Canada
Principal Financial Group Inc. Reduces Stock Position in Nuvation Bio Inc. (NYSE:NUVB) - Defense World
Nuvation Bio's SWOT analysis: oncology firm's stock faces pivotal year - Investing.com
Nuvation Bio's (NUVB) Outperform Rating Reiterated at Royal Bank of Canada - MarketBeat
Nuvation Bio (NYSE:NUVB) Shares Gap UpHere's What Happened - MarketBeat
FDA progress and strong trial data drive positive outlook for Nuvation Bio stock - Investing.com Australia
Nuvation Bio (NYSE:NUVB) Given Buy Rating at HC Wainwright - Defense World
Nuvation Bio price target raised to $10 from $6 at RBC Capital - Nasdaq
Nuvation Bio’s (NUVB) “Outperform” Rating Reaffirmed at Wedbush - Defense World
Wedbush Reiterates Outperform Rating for Nuvation Bio (NYSE:NUVB) - MarketBeat
Nuvation Bio to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Lelezard
Nuvation Bio Receives Approval from China’s National Medical Products Administration for Taletrectinib for Patients with Advanced ROS1-positive Non-Small Cell Lung Cancer - BioSpace
Nuvation Bio Inc (NUVB) 財務データ
収益
当期純利益
現金流量
EPS
0.27%
3.05%
大文字化:
|
ボリューム (24 時間):